| Entry |
|
|---|
| Name |
Travoprost (JAN/USAN/INN);
Travatan (TN)
|
|---|
| Product |
|
|---|
| Generic |
|
|---|
| Formula |
C26H35F3O6
|
|---|
| Exact mass |
500.2386
|
|---|
| Mol weight |
500.5477
|
|---|
| Structure |
     |
|---|
| Simcomp |
 |
|---|
| Class |
Other
DG01961 Prostaglandin derivative
DG01960 Prostaglandin F derivative
|
|---|
| Remark |
Therapeutic category: ATC code: |
|---|
| Activity |
Antiglaucoma, Prostaglandin F receptor agonist |
|---|
| Comment |
PProstaglandin derivative
Treatment of elevated intraocular pressure associated with glaucoma
|
|---|
| Target |
|
|---|
| Pathway |
| Calcium signaling pathway | | Neuroactive ligand-receptor interaction |
|
|---|
| Interaction |
|
|---|
| Structure map |
| Prostaglandins | | Antiglaucoma agents | | Eicosanoid receptor agonists/antagonists |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
S SENSORY ORGANS
S01 OPHTHALMOLOGICALS
S01E ANTIGLAUCOMA PREPARATIONS AND MIOTICS
S01EE Prostaglandin analogues
S01EE04 Travoprost
D01964 Travoprost (JAN/USAN/INN)
USP drug classification [BR:br08302]
Ophthalmic Agents
Ophthalmic Prostaglandin and Prostamide Analogs
Travoprost
D01964 Travoprost (JAN/USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
1 Agents affecting nervous system and sensory organs
13 Agents affecting sensory organs
131 Ophthalmic agents
1319 Others
D01964 Travoprost (JAN/USAN/INN)
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Rhodopsin family
Prostaglandin
prostaglandin F receptor
Travoprost
D01964 Travoprost (JAN/USAN/INN)
New drug approvals in the USA [br08319.html]
New Molecular Entity and New Therapeutic Biological Product Approvals
D01964
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D01964
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D01964
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D01964
 |
|---|
| Other DBs |
CAS: 157283-68-6 PubChem: ChEBI: ChEMBL: DrugBank: LigandBox: NIKKAJI: |
|---|
| KCF data |
ATOM 35
1 C1y C 19.2500 -20.4400
2 C1y C 19.2500 -21.8400
3 C1y C 17.8500 -20.0200
4 C1b C 20.4400 -19.7400
5 C1y C 17.9200 -22.2600
6 C2b C 20.4400 -22.5400
7 C1x C 17.0800 -21.1400
8 C2b C 21.6300 -20.4400
9 O1a O 17.5000 -23.6600
10 C2b C 21.6300 -21.8400
11 C1c C 22.8900 -22.5400
12 C1b C 24.0800 -21.8400
13 O1a O 22.8900 -23.9400
14 O2a O 25.3400 -22.5400
15 C8y C 25.3400 -23.9400
16 C8x C 26.5300 -24.6400
17 C8y C 26.5300 -26.0400
18 C8x C 25.3400 -26.7400
19 C8x C 24.0800 -26.0400
20 C8x C 24.0800 -24.6400
21 O1a O 17.3600 -18.6900
22 C2b C 23.0300 -20.4400
23 C1b C 24.2200 -19.7400
24 C1b C 25.4100 -20.4400
25 C1b C 26.6000 -19.7400
26 C7a C 27.7900 -20.4400
27 O7a O 28.9800 -19.7400
28 C1c C 30.1700 -20.4400
29 C1a C 31.3600 -19.7400
30 O6a O 27.7900 -21.8400
31 C1a C 30.1700 -21.8400
32 C1d C 27.7453 -26.7351
33 X F 28.9337 -26.0423
34 X F 27.7511 -28.1397
35 X F 28.9435 -27.4205
BOND 36
1 12 14 1
2 5 7 1
3 14 15 1
4 1 2 1
5 1 3 1
6 1 4 1 #Down
7 2 5 1
8 2 6 1 #Up
9 15 16 2
10 16 17 1
11 17 18 2
12 18 19 1
13 19 20 2
14 20 15 1
15 3 7 1
16 4 8 1
17 5 9 1 #Down
18 6 10 2
19 10 11 1
20 11 12 1
21 11 13 1 #Down
22 3 21 1 #Down
23 8 22 2
24 23 24 1
25 23 22 1
26 24 25 1
27 25 26 1
28 26 27 1
29 27 28 1
30 28 29 1
31 26 30 2
32 28 31 1
33 17 32 1
34 32 33 1
35 32 34 1
36 32 35 1
|
|---|
